FindTrial
Sign In

Retrospective study on the effect of traditional Chinese medicine on prognosis of patients with advanced gastric cancer after surgery and analysis of related risk factors

Clinical study of Yiqi Huayu Jiedu decoction regulating immune cells to reduce the risk of recurrence and metastasis of stage III gastric cancer after operation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025001577
Enrollment
Unknown
Registered
2025-08-19
Start date
2023-06-08
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Non-exposed group:chemotherapy
Exposed group:chemotherapy+TCM

Sponsors

Jiangsu Province Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1)Meet the diagnostic criteria for gastric adenocarcinoma and have undergone radical surgery; (2) Postoperative adjuvant chemotherapy with XELOX as the main regimen; (3) If oral Chinese medicine prescription Yiqi Huayu Jiedu prescription mainly added or reduced; (4) 18 years old =90 years old; (5) Clearly aware of being able to complete the questionnaire independently or with the help of family members; (6) Agree to participate in this research.

Exclusion criteria

Exclusion criteria: (1) Patients diagnosed with metastatic gastric cancer at the first diagnosis whose local recurrence or distant metastasis has been confirmed by histopathology or imaging examination; (2) Pathological diagnosis of gastric stromal tumor neuroendocrine carcinoma lymphoma squamous cell carcinoma and other non-adenocarcinoma types; (3) The presence or occurrence of malignant tumors in other parts of the body including high-grade intraepithelial neoplasia and severe dysplasia in esophagus intestine and cervix; (4) Patients undergoing palliative surgery; (5) Gender age operation time postoperative pathological results and other data in the data are incomplete and irreparable resulting in the inability to judge the stage recurrence and metastasis time; (6) There are cognitive and communication barriers unable to cooperate with the investigation; (7) Complicated with serious primary heart liver lung kidney blood or serious diseases affecting their survival.

Design outcomes

Primary

MeasureTime frame
disease-free survival;Cellular immune function;One-year and two-year progression-free survival rates;—

Secondary

MeasureTime frame
Life Quality Score;Overall chemotherapy completion rate;Traditional Chinese Medicine Syndrome Score;Tumor marker;—

Countries

China

Contacts

Public ContactCunen Wu

Jiangsu Province Hospital of Chinese Medicine

714494480@qq.com+86 15651660263

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026